Scholarlink

Background <p>Neutrophil gelatinase-associated lipocalin (NGAL) is present in secondary granules of neutrophils and it is a relatively newly recognized marker of kidney diseases. The fibrinogen-to-albumin ratio (FAR) is a marker of inflammation but its diagnostic value has not been determined in sickle cell disease patients with kidney diseases. This study investigated the diagnostic roles of serum neutrophil gelatinase-associated lipocalin (sNGAL) and FAR for kidney diseases in steady-state adult sickle cell disease (SCD) patients.</p> Methods <p>This study employed a prospective case-control design and recruited 104 SCD participants and 80 non-SCD patients. Participants’ information was thoroughly documented using a structured questionnaire and patient case records. To evaluate the hematobiochemical parameters, 5&#xa0;ml of venous blood was drawn from each participant and a clean catch of midstream urine was collected from each participant. The cases and controls were further categorized into microalbuminuria and non-microalbuminuria subjects, following three consecutive urine albumin-to-creatinine ratio (UACR) measurements.</p> Results <p>The prevalence of microalbuminuria was 32.7% among adult steady-state SCD patients. Significant higher levels of sNGAL and FAR were detected in SCD patients with microalbuminuria than in SCD patients without microalbuminuria and controls (<i>p</i> &lt; 0.001). A moderate positive correlation was observed between sNGAL and UACR (<i>r</i> = 0.45, <i>p</i> = 0.007). A unit increase in sNGAL (cOR: 3.25 (2.11-5.00); <i>p</i> &lt; 0.001), aOR: 3.35(2.09–5.36); <i>p</i> &lt; 0.0001)) and FAR (Log cOR: 12.26 (1.82–25.09); <i>p</i> = 0.022) were significantly associated with increased odds of kidney disease among SCD participants. sNGAL emerged as a highly early predictive marker for kidney disease in SCD patients, with a cutoff value of &gt; 5.72&#xa0;µg/L yielding a high area under the curve (AUC = 0.854, <i>p</i> &lt; 0.0001). sNGAL also demonstrated an excellent sensitivity (91.2%) and moderate specificity (74.7%). The FAR at a cutoff of &gt; 0.09 also demonstrated significant predictive value (AUC = 0.630, <i>p</i> = 0.009) for kidney disease in SCD patients, with a moderate sensitivity (67.6%) and specificity (61.3%).</p> Conclusion <p>Based on our findings, sNGAL could serve as an independent early predictor of kidney disease compared with urea and creatinine. Additionally, the fibrinogen-to-albumin ratio can be used as inflammatory marker for kidney diseases in SCD patients.</p> Clinical trial number <p>Not applicable.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Neutrophil gelatinase-associated lipocalin and fibrinogen-to-albumin ratio are indicators of kidney disease in sickle cell disease patients with microalbuminuria: a multicentre case-control study in Ghana

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月29日

查看全文
  • Stephen Twumasi,
  • Enoch Odame Anto,
  • Christian Obirikorang,
  • Richard Kobina Dadzie Ephraim,
  • Benedict Sackey,
  • Vivian Paintsil,
  • Richard Owusu Ansah,
  • Alfred Effah,
  • Allwell Adofo Ayirebi,
  • Angela Opoku,
  • Godfred Yawson Scott,
  • Leslie Osei,
  • Joyce Duku,
  • Emmanuel Asafo Adjei,
  • Lilian Antwi Boateng

摘要

Background

Neutrophil gelatinase-associated lipocalin (NGAL) is present in secondary granules of neutrophils and it is a relatively newly recognized marker of kidney diseases. The fibrinogen-to-albumin ratio (FAR) is a marker of inflammation but its diagnostic value has not been determined in sickle cell disease patients with kidney diseases. This study investigated the diagnostic roles of serum neutrophil gelatinase-associated lipocalin (sNGAL) and FAR for kidney diseases in steady-state adult sickle cell disease (SCD) patients.

Methods

This study employed a prospective case-control design and recruited 104 SCD participants and 80 non-SCD patients. Participants’ information was thoroughly documented using a structured questionnaire and patient case records. To evaluate the hematobiochemical parameters, 5 ml of venous blood was drawn from each participant and a clean catch of midstream urine was collected from each participant. The cases and controls were further categorized into microalbuminuria and non-microalbuminuria subjects, following three consecutive urine albumin-to-creatinine ratio (UACR) measurements.

Results

The prevalence of microalbuminuria was 32.7% among adult steady-state SCD patients. Significant higher levels of sNGAL and FAR were detected in SCD patients with microalbuminuria than in SCD patients without microalbuminuria and controls (p < 0.001). A moderate positive correlation was observed between sNGAL and UACR (r = 0.45, p = 0.007). A unit increase in sNGAL (cOR: 3.25 (2.11-5.00); p < 0.001), aOR: 3.35(2.09–5.36); p < 0.0001)) and FAR (Log cOR: 12.26 (1.82–25.09); p = 0.022) were significantly associated with increased odds of kidney disease among SCD participants. sNGAL emerged as a highly early predictive marker for kidney disease in SCD patients, with a cutoff value of > 5.72 µg/L yielding a high area under the curve (AUC = 0.854, p < 0.0001). sNGAL also demonstrated an excellent sensitivity (91.2%) and moderate specificity (74.7%). The FAR at a cutoff of > 0.09 also demonstrated significant predictive value (AUC = 0.630, p = 0.009) for kidney disease in SCD patients, with a moderate sensitivity (67.6%) and specificity (61.3%).

Conclusion

Based on our findings, sNGAL could serve as an independent early predictor of kidney disease compared with urea and creatinine. Additionally, the fibrinogen-to-albumin ratio can be used as inflammatory marker for kidney diseases in SCD patients.

Clinical trial number

Not applicable.